Cargando…

Two-stage optimal designs with survival endpoint when the follow-up time is restricted

BACKGROUND: Survival endpoint is frequently used in early phase clinical trials as the primary endpoint to assess the activity of a new treatment. Existing two-stage optimal designs with survival endpoint either over estimate the sample size or compute power outside the alternative hypothesis space....

Descripción completa

Detalles Bibliográficos
Autores principales: Shan, Guogen, Zhang, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448233/
https://www.ncbi.nlm.nih.gov/pubmed/30943896
http://dx.doi.org/10.1186/s12874-019-0696-x
_version_ 1783408659010682880
author Shan, Guogen
Zhang, Hua
author_facet Shan, Guogen
Zhang, Hua
author_sort Shan, Guogen
collection PubMed
description BACKGROUND: Survival endpoint is frequently used in early phase clinical trials as the primary endpoint to assess the activity of a new treatment. Existing two-stage optimal designs with survival endpoint either over estimate the sample size or compute power outside the alternative hypothesis space. METHODS: We propose a new single-arm two-stage optimal design with survival endpoint by using the one-sample log rank test based on exact variance estimates. This proposed design with survival endpoint is analogous to Simon’s two-stage design with binary endpoint, having restricted follow-up. RESULTS: We compare the proposed design with the existing two-stage designs, including the two-stage design with survival endpoint based on the nonparametric Nelson-Aalen estimate, and Simon’s two-stage designs with or without interim accrual. The new design always performs better than these competitors with regards to the expected total study length, and requires a smaller expected sample size than Simon’s design with interim accrual. CONCLUSIONS: The proposed two-stage minimax and optimal designs with survival endpoint are recommended for use in practice to shorten the study length of clinical trials.
format Online
Article
Text
id pubmed-6448233
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64482332019-04-15 Two-stage optimal designs with survival endpoint when the follow-up time is restricted Shan, Guogen Zhang, Hua BMC Med Res Methodol Research Article BACKGROUND: Survival endpoint is frequently used in early phase clinical trials as the primary endpoint to assess the activity of a new treatment. Existing two-stage optimal designs with survival endpoint either over estimate the sample size or compute power outside the alternative hypothesis space. METHODS: We propose a new single-arm two-stage optimal design with survival endpoint by using the one-sample log rank test based on exact variance estimates. This proposed design with survival endpoint is analogous to Simon’s two-stage design with binary endpoint, having restricted follow-up. RESULTS: We compare the proposed design with the existing two-stage designs, including the two-stage design with survival endpoint based on the nonparametric Nelson-Aalen estimate, and Simon’s two-stage designs with or without interim accrual. The new design always performs better than these competitors with regards to the expected total study length, and requires a smaller expected sample size than Simon’s design with interim accrual. CONCLUSIONS: The proposed two-stage minimax and optimal designs with survival endpoint are recommended for use in practice to shorten the study length of clinical trials. BioMed Central 2019-04-03 /pmc/articles/PMC6448233/ /pubmed/30943896 http://dx.doi.org/10.1186/s12874-019-0696-x Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Shan, Guogen
Zhang, Hua
Two-stage optimal designs with survival endpoint when the follow-up time is restricted
title Two-stage optimal designs with survival endpoint when the follow-up time is restricted
title_full Two-stage optimal designs with survival endpoint when the follow-up time is restricted
title_fullStr Two-stage optimal designs with survival endpoint when the follow-up time is restricted
title_full_unstemmed Two-stage optimal designs with survival endpoint when the follow-up time is restricted
title_short Two-stage optimal designs with survival endpoint when the follow-up time is restricted
title_sort two-stage optimal designs with survival endpoint when the follow-up time is restricted
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448233/
https://www.ncbi.nlm.nih.gov/pubmed/30943896
http://dx.doi.org/10.1186/s12874-019-0696-x
work_keys_str_mv AT shanguogen twostageoptimaldesignswithsurvivalendpointwhenthefollowuptimeisrestricted
AT zhanghua twostageoptimaldesignswithsurvivalendpointwhenthefollowuptimeisrestricted